Prophylactic Level VII Nodal Dissection as a Prognostic Factor in Papillary Thyroid Carcinoma: a Pilot Study of 27 Patients

Ihab Samy Fayek

Abstract

Background: Prognostic value of prophylactic level VII nodal dissection in papillary thyroid carcinoma has been highlighted. Materials and Methods: A total of 27 patients with papillary thyroid carcinoma with N0 neck underwent total thyroidectomy with level VI and VII nodal dissection through same collar neck incision. Multicentricity, bilaterality, extrathyroidal extension, level VI and VII lymph nodes were studied as separate and independent prognostic factors for DFS at 24 months. Results: 21 females and 6 males with a mean age of 34.6 years old, tumor size was 5-24 mm. (mean 12.4 mm.), multicentricity in 11 patients 2-4 foci (mean 2.7), bilaterality in 8 patients and extrathyroidal extension in 8 patients. Dissected level VI LNs 2-8 (mean 5 LNs) and level VII LNs 1-4 (mean 1.9). Metastatic level VI LNs 0-3 (mean 1) and level VII LNs 0-2 (mean 0.5). Follow-up from 6-51 months (mean 25.6) with 7 patients showed recurrence (3 local and 4 distant). Cumulative DFS at 24 months was 87.8% and was significantly affected in relation to bilaterality (p-value <0.001), extrathyroidal extension (p-value <0.001), level VI positive ((p-value <0.001) and level VII positive ((p-value <0.001) LNs. No recurrences were detected during the follow-up period in the absence of level VI and level VII nodal involvement. Conclusions: Level VII prophylactic nodal dissection is an important and integral prognostic factor in papillary thyroid carcinoma. A larger multicenter study is crucial to reach a satisfactory conclusion about the necessity and safety of this approach.

Keywords: Level VII - central nodal dissection - papillary thyroid carcinoma
Ihab Samy Fayek


14% and 44%. For White et al., 2007 the rate of permanent hypoparathyroidism after total thyroidectomy (TT) with prophylactic CND is between 0% and 14.3%.

Many studies showed an increased risk of recurrent paralysis in patients undergoing CND, with rates of recurrent lesions ranging between 1% and 12% (Hughes and Doherty, 2011).

According to Popadich et al. (2011) the percentage of recurrent transient paralysis increased from 1.8% after TT to 2.3% after TT with CND, whereas the definitive rates range from 0.4% to 1.8%. For Giordano et al., 2012 transitional cases range from 3.6% to 5.5%, the definitive from 1% to 2.3%.

This pilot study was designed to study the prognostic value of prophylactic level VII nodal dissection in PTC and its importance among other prognostic factors.

Materials and Methods

From November 2009 to April 2013, 27 patients diagnosed with papillary thyroid carcinoma (confirmed by U/S guided FNAC) underwent total thyroidectomy and prophylactic nodal dissection of the central neck nodes (level VI) in addition to the superior mediastinal nodes (level VII) all through the low collar neck incision.

All patients had no clinical nor sonographic evidence of nodal metastases pre-operatively. The limits of dissection was the hyoid bone (above), the left innominate vein (below) and the internal jugular veins on both sides (laterally).

The 3 specimens were submitted intraoperatively in separate containers for histopathological examination as follows:

i) Total thyroidectomy specimen; ii) Level VI group of lymph nodes (including the prelaryngeal, pretracheal, and paratracheal nodes between the hyoid bone and the suprasternal notch); iii) Level VII group of lymph nodes (defined as the pretracheal and paratracheal superior mediastinal lymph nodes between the suprasternal notch and the innominate vein).

Patient demographics, number of nodes removed, percentage of nodes involved by malignancy, and size of the metastases were recorded and analyzed. A single pathologist reviewed all histology of patients. This project was approved by the Institutional Ethics Committee.

Data were analyzed using IBM SPSS Advanced Statistics version 20.0 (SPSS Inc., Chicago, IL). Chi-square test (Fisher’s exact test) was used to examine the relation between qualitative variables. Survival analysis was done using the Kaplan-Meier method and comparison between two survival curves was done using log-rank test. A p-value < 0.05 was considered significant.

Results

Twenty one females and six males were included in the study, the age was 22-51 years old (mean 34.6). Tumor size was 5-24 mm. in maximum diameter (mean 12.4 mm.). Multicentricity was observed in 11 patients with 2-4 foci (mean 2.7) where two foci in 5 patients (45.5%), three foci in 4 patients (36.4%) and four foci in 2 patients (18.2%). Bilaterality was observed in 8 patients (29.6%). Extrathyroidal extension was also observed in 8 patients (29.6%). The number of dissected level VI lymph nodes ranged from 2-8 LNs (mean 5 LNs) and the number of dissected level VII lymph nodes ranged from 1-4 LNs (mean 1.9 LN). The number of metastatic level VI lymph nodes ranged from 0-3 LNs (mean 1 LN) and The number of metastatic level VII lymph nodes ranged from 0-2 LNs

Table 1. Cumulative DFS at 24 Months for the Study Population in Relation to the Prognostic Factors  

<table>
<thead>
<tr>
<th></th>
<th>Number</th>
<th>Cumulative Disease Free Survival</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cases</td>
<td>27</td>
<td>87.80%</td>
<td></td>
</tr>
<tr>
<td>Multicentricity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>11</td>
<td>81.80%</td>
<td>0.004</td>
</tr>
<tr>
<td>No</td>
<td>16</td>
<td>92.30%</td>
<td></td>
</tr>
<tr>
<td>Bilaterality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>8</td>
<td>75.00%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>No</td>
<td>19</td>
<td>93.80%</td>
<td></td>
</tr>
<tr>
<td>Extrathyroidal Extension</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>8</td>
<td>62.50%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>No</td>
<td>19</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>Level VI lymph nodes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>15</td>
<td>79.00%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Negative</td>
<td>12</td>
<td>100.00%</td>
<td></td>
</tr>
<tr>
<td>Level VII lymph nodes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>11</td>
<td>72.70%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Negative</td>
<td>16</td>
<td>100%</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Correlation between Cumulative Disease Free Survival and Level VI Nodes

Figure 2. Correlation between Cumulative Disease Free Survival and Level VII Nodes
Discussion

Putting in mind that in PTC, lymph node metastases have been shown to increase the risk of locoregional tumor recurrence (Hay et al., 1999; Leboulleux et al., 2005; Cheema et al., 2006; Ito and Miyauchi, 2007) and that approximately 5% of patients with PTC were identified as having superior mediastinal metastases (Roh et al., 2008; Machens and Dralle, 2009) with concerns that metastatic lymph node involvement is nothing more than indolent microscopic disease without clinical significance and that the sensitivity of ultrasound and CT range between only 50 and 70% Mulla, (2012), and on the other hand Wang et al., 2013 advocated the unnecessary CND in some patients with incidental PTC postoperatively and that the impact of positive regional lymph nodes on survival has been controversial (Steinmuller et al., 2000), we performed a prophylactic CND including level VI and VII from the same collar neck incision (Block et al., 1972). Yu et al., 2012 recommended the “wait and see” strategy for clinically negative level V in low risk PTC patients and stated that it would still achieve good survival results. As is recommended for the other nodal groups, dissection of the superior mediastinal lymph nodes should it be performed in the presence of gross nodal involvement? Some investigators advocate for routine prophylactic superior mediastinal dissection in patients with PTC; however, data indicating a survival or recurrence advantage are lacking (Fritze and Doherty, 2010). In this study, a DFS advantage at 24 months was statistically significant in patients with negative metastases to levels VI and VII lymph nodes; in addition, no recurrences were detected neither clinically nor radiologically in all those patients during the follow-up period which reached up to 51 months. These results suggest the importance of dissecting these nodes, they also re-enforce and support the study of Laura et al., 2013 who performed prophylactic Level VI and VII nodal dissection on 32 patients with PTC concluding the importance and safety of level VII nodal dissection and that failure to include this level will leave significant macrometastatic nodal disease in situ.

Inspite the low incidence of permanent hypoparathyroidism (7.4%) and permanent recurrent laryngeal dysfunction (3.7%) in this study, which is comparable to other studies in the literature (White et al., 2007; Popadich et al., 2011; Giordano et al., 2012), we cannot conclude the safety of the procedure as regards those two parameters as this may need a larger sample size in a multicenter study with a multivariate analysis comparing another group of patients who didn’t have a prophylactic Level VII nodal dissection.

In conclusion, level VII (as well as level VI) prophylactic nodal dissection is an important prognostic indicator in PTC and should be performed in all patients with clinically and radiologically N0 neck. A multivariate analysis along a multicenter study with a larger number of patients must be performed to reach a satisfactory conclusion about the necessity and safety of level VII nodal dissection.

References

Dralle H (2013). Prophylactic central lymph node dissection improves prognosis for papillary thyroid cancer, Chirurg, 84, 149.
Hay I, Bergstrahl E, Grant C, et al (1999). Impact of primary surgery on outcome in 300 patients with pathologic tumor-node metastasis stage II papillary thyroid carcinoma treated at one institution from 1940 through. Surgery, 126, 1173-81;

DOI:http://dx.doi.org/10.7314/APJCP.2015.16.10.4211

Prophylactic Level VII Nodal Dissection as a Prognostic Factor in Papillary Thyroid Carcinoma: a Pilot Study of 27 patients

Asian Pacific Journal of Cancer Prevention, Vol 16, 2015 4213


